Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Co-Midis
- Development stage
- Phase 4
- Lead developer
- Standard Chem & Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Co-Midis is an oral fixed-dose combination antihypertensive medication developed by Standard Chem & Pharm. It contains telmisartan, an angiotensin II type 1 (AT1) receptor blocker (ARB) and partial peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, and amlodipine, a dihydropyridine L-type calcium channel blocker. By combining these two complementary mechanisms of action, Co-Midis effectively promotes vasodilation and reduces peripheral vascular resistance to lower blood pressure. It is approved for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy or as replacement therapy for patients already receiving both components separately.
- Brand names
- Co-MidisCo-Midis Tab.Co-Midis Tablets倍壓妥倍壓妥錠
- Other names
- amlodipine + telmisartantelmisartan + amlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Co-Midis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Co-Midis.